Alzheimer’s digest – 2021 Alzheimer’s digest – 2021 Galimedix accelerating development for GAL-201 GAL-201 (Anti amyloid-β) – Galimedix Galimedix announced an accelerated program for its oral small molecule GAL-201 targeting amyloid-β oligomers Planning for FIH within one year In preclinical […]
Alzheimer’s digest – 2021 Alzheimer’s digest – 2021 Synaptogenix raised $12.5 M and announced Phase 2b Bryostatin-1 clinical trial update Bryostatin-1 (Protein kinase C (PKC) agonist) – Synaptogenix The net proceeds of the private placement will be used to fund […]
Alzheimer’s digest – 2021 Alzheimer’s digest – 2021 Axon Neuroscience published ADAMANT Phase 2 study of AAdvac1 AADvac1 (Alzheimer’s tau vaccine) – Axon Neuroscience Trial details: ADAMANT; Phase 2 in mild Alzheimer’s disease; N= 196; AADvac1 40 µg SC Q4W […]
Alzheimer’s digest – 2021 Alzheimer’s digest – 2021 BioVie announced closing of acquisition of biopharma assets from privately held NeurMedix NE3107 (ERK inhibitor) – BioVie/ NeurMedix The acquired assets include NE3107, a selective inhibitor of inflammatory ERK signaling that reduces […]
